Improvement by affinity chromatography on antiidiotypic monoclonal antibodies (MAbs) of immunoreactivity and in vivo targeting of radiolabelled anti-HMW-MAA MAb TP61.5 in nude mice bearing human melanoma lesions
- PMID: 1917164
- DOI: 10.1002/ijc.2910490426
Improvement by affinity chromatography on antiidiotypic monoclonal antibodies (MAbs) of immunoreactivity and in vivo targeting of radiolabelled anti-HMW-MAA MAb TP61.5 in nude mice bearing human melanoma lesions
Abstract
The human high-molecular-weight melanoma-associated antigen (HMW-MAA) represents a useful marker for immunoscintigraphy in patients with melanoma. Since injection of a radiolabelled anti-HMW-MAA monoclonal antibody (MAb) visualizes only about 60% of melanoma lesions, approaches are being developed to increase the sensitivity of immunoscintigraphy. One of them aims at improving the immunoreactivity of radiolabelled anti-HMW-MAA MAbs, since this approach may improve the targeting of radiolabelled MAbs to melanoma lesions. We have previously shown that affinity chromatography on insolubilized anti-idiotypic MAbs is a useful method for purifying immunoreactive anti-HMW-MAA MAb TP61.5 from 125I-labelled MAb preparations and that not all the anti-idiotypic MAbs are useful for this purpose. Since the increasing number of available anti-idiotypic MAbs is likely to facilitate the application of this procedure in many antigenic systems, we have now tested criteria to select anti-idiotypic MAbs suitable for the purification procedure. Furthermore, we have investigated the effect of the increase in immunoreactivity of 125I-MAb TP61.5 on its in vivo targeting to human melanoma lesions transplanted into nude mice. Among the 3 anti-idiotypic MAbs tested, the most effective in purifying immunoreactive MAb TP61.5 molecules following radiolabelling is MAb TK7-110, with which 125I-MAb TP61.5 displays an immunoreactivity similar to that displayed with melanoma cells. This parameter may represent a useful criterion to identify anti-idiotypic MAbs suitable for the purification procedure, if the present results are confirmed with a large number of anti-idiotypic MAbs in different antigenic systems. We have also shown that an incubation time for up to 4 hr of 125I-MAb TP61.5 with insolubilized MAb TK7-110 is the most effective in increasing immunoreactivity and in recovering immunoreactive MAb applied to the affinity matrix. The increase in the immunoreactive fraction of 125I-MAb TP61.5 significantly increases its specific localization in human melanoma lesions transplanted into nude mice. These results suggest that purification of radiolabelled immunoreactive anti-HMW-MAA MAb TP61.5 by affinity chromatography using anti-idiotypic MAb TK7-110 represents a useful approach to increasing the sensitivity of immunoscintigraphy in patients with melanoma.
Similar articles
-
Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371.Cancer Res. 1991 Sep 15;51(18):4790-7. Cancer Res. 1991. PMID: 1716513
-
Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen.Cancer Res. 1992 May 1;52(9):2497-503. Cancer Res. 1992. PMID: 1373670
-
Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23.Int J Cancer. 1998 Nov 9;78(4):486-90. doi: 10.1002/(sici)1097-0215(19981109)78:4<486::aid-ijc15>3.0.co;2-4. Int J Cancer. 1998. PMID: 9797138
-
Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma.Pharmacol Ther. 1993 Feb-Mar;57(2-3):259-90. doi: 10.1016/0163-7258(93)90058-l. Pharmacol Ther. 1993. PMID: 8361995 Review.
-
Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms.Ann N Y Acad Sci. 2004 Dec;1028:340-50. doi: 10.1196/annals.1322.040. Ann N Y Acad Sci. 2004. PMID: 15650259 Review.
Cited by
-
Theranostic impact of NG2/CSPG4 proteoglycan in cancer.Theranostics. 2015 Feb 15;5(5):530-44. doi: 10.7150/thno.10824. eCollection 2015. Theranostics. 2015. PMID: 25767619 Free PMC article. Review.
-
Immunoscintigraphy for ocular melanoma: a reliable diagnostic technique?Graefes Arch Clin Exp Ophthalmol. 1996 Feb;234(2):100-4. doi: 10.1007/BF00695248. Graefes Arch Clin Exp Ophthalmol. 1996. PMID: 8720679
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical